Evidence map›Paper›PMID 37324533›Full record

ArticleNeurology. Clinical practice2023

Study to Assess Content Validity and Interrater and Intrarater Reliability of the Inclusion Body Myositis Functional Rating Scale.

Tara Symonds, Jason Randall, Lucy Lloyd-Price, Stacie Hudgens, Mazen M Dimachkie, Christina Guldberg, Pedro M Machado

Abstract read
In one paragraph

Article in Neurology. Clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tara SymondsClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Jason RandallClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Lucy Lloyd-PriceClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Stacie HudgensClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Mazen M DimachkieClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID https://orcid.org/0000-0002-7148-989X
Christina GuldbergClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Pedro M MachadoClinical Outcomes Solutions (TS, JR, LL-P), Folkestone, United Kingdom; Clinical Outcomes Solutions (SH), Tucson, AZ; The University of Kansas Medical Center (MMD); Orphazyme A/S (CG), Copenhagen, Denmark; and Department of Neuromuscular Diseases (PMM), UCL Queen Square Institute of Neurology, University College London, United Kingdom.ORCID https://orcid.org/0000-0002-8411-7972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Sporadic inclusion body myositis (IBM) is a rare, muscle-wasting disease that negatively affects health-related quality of life. Although a measure that has been developed to assess the impact of IBM, the IBM Functional Rating Scale (IBMFRS) has limited evidence of content validity or reliability, and what constitutes a meaningful change threshold; this study was conducted to address these gaps. Methods: Adult patients with a clinical diagnosis of IBM from the United Kingdom and disease area expert health care professionals from the United States and United Kingdom took part in this study. This study consisted of 5 stages including phone interviews (physicians), face-to-face interviews (patients), face-to-face ratings, phone ratings, and ratings of videos using the IBMFRS. Results: The IBMFRS adequately captures all core functional impacts of IBM, which was corroborated by both patient participants and physicians when debriefing the measure. Physicians and patient participants all thought any change on the measure would be meaningful change for a patient, either improvement or worsening. The quantitative analysis demonstrated good interrater reliability for face-to-face ratings (intraclass correlation coefficient [ICC] >0.7) and for video ratings (ICC >0.9). Intrarater reliability was excellent for face-to-face and video ratings (ICC >0.9). Equivalence between the modes of administration, face-to-face vs phone, was also excellent (ICC >0.9). Discussion: The IBMFRS is content valid in assessing the key functional impacts of IBM, and any change would be meaningful. It is reliable both within and across raters, and there is equivalence between different modes of administration (face-to-face vs phone).

Identifiers

PMID37324533
PMCPMC10263485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.